<DOC>
	<DOCNO>NCT01097070</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics ( behavior body ) bevirimat administer 15 day HIV-positive individual .</brief_summary>
	<brief_title>A Phase 2 Study Assess Pharmacokinetics Bevirimat 100 mg Tablets Given HIV-1 Positive Patient 15 Days</brief_title>
	<detailed_description />
	<criteria>Have documentation HIV1 infection medical record ( documentation prior plasma viremia acceptable ) . Have CD4+ lymphocyte count &gt; /= 100 cells/mm3 . Have screen plasma HIV1 RNA value , measure Roche Amplicor assay , &lt; 400 copies/mL . Be receive ARV therapy regimen contain least 3 drug unchanged least 8 week prior screen , continue Day 15 study . Be informed nature study provide write informed consent . Be legally competent able communicate effectively study personnel . Be able willing comply outpatient visit . Presence acute illness within 14 day prior study entry . Presence AIDSrelated opportunistic infection ( Category C accord CDC Classification System HIV1 Infection , 1993 Revised Version ) unstable Investigator 's opinion diagnose 30 day prior study entry . Patients , opinion Investigator , unable comply dose schedule protocol evaluation . Patients malabsorption syndromes affect drug absorption ( e.g . Crohn 's disease , chronic pancreatitis ) . Patients systolic blood pressure &lt; 90 mmHg &gt; 160 mmHg diastolic blood pressure &lt; 50 mmHg &gt; 110 mmHg . A history seizure ( exclude pediatric febrile seizure ) current administration prophylactic antiseizure medication indication seizure seizurerelated condition . A history cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . Patients receive radiation therapy cytotoxic chemotherapeutic agent within 4 week prior first dose study drug . Patients receive treatment immunomodulating agent IL2 , alphainterferon , betainterferon , gammainterferon within 4 week prior first dose study drug . Receipt investigational drug product , participation drug study within period 30 day prior receive study medication . Bupropioncontaining product require least 14day washout period approve coadministration . Rifampin rifamycin product require least 28day washout period approve coadministration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>